The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.
Sian Alexandra Pugh
No relevant relationships to disclose
Alexandre Ball
No relevant relationships to disclose
Megan Bowers
No relevant relationships to disclose
Stephen Falk
Consultant or Advisory Role - Merck
Meg Finch-Jones
No relevant relationships to disclose
Juan W. Valle
Honoraria - Merck
Research Funding - Merck
Derek O'Reilly
No relevant relationships to disclose
Ajith K. Siriwardena
No relevant relationships to disclose
Joanne Hornbuckle
No relevant relationships to disclose
Myrddin Rees
No relevant relationships to disclose
Tim Iveson
Consultant or Advisory Role - Merck
Tom Maishman
No relevant relationships to disclose
Elizabeth Dixon
No relevant relationships to disclose
Andrea Corkhill
No relevant relationships to disclose
Mike Radford
No relevant relationships to disclose
O James Garden
No relevant relationships to disclose
David Cunningham
Research Funding - Amgen; Celgene; Merck Serono; Roche; Sanofi
Tim Maughan
Consultant or Advisory Role - Merck Serono
John A. Bridgewater
Consultant or Advisory Role - Bayer; Merck; Roche; Sanofi
John Neil Primrose
Consultant or Advisory Role - Bayer; Merck; Sanofi
Research Funding - Merck